As a step to develop a potential novel therapy vector for MTC, with improvements over previous vectors, we engineered a double-stranded rAAV-based gene therapy vector (GTV) to express transgenes under the control of a modified, truncated (765 bp) calcitonin promoter (pM+104) [17]. The gene discussed is CALCA; the disease is medullary thyroid gland carcinoma.